Is Cullinan Oncology Stock a Good Investment?
Cullinan Oncology Investment Advice | CGEM |
- Examine Cullinan Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cullinan Oncology's leadership team and their track record. Good management can help Cullinan Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cullinan Oncology's business and its evolving consumer preferences.
- Compare Cullinan Oncology's performance and market position to its competitors. Analyze how Cullinan Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Cullinan Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cullinan Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cullinan Oncology LLC stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cullinan Oncology LLC is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cullinan Oncology Stock
Researching Cullinan Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cullinan Oncology LLC recorded a loss per share of 2.84. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 31st of August 2009.
To determine if Cullinan Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cullinan Oncology's research are outlined below:
| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cullinan Oncology stock hits 52-week low at 8.99 - Investing.com India |
Cullinan Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cullinan Oncology LLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cullinan Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cullinan Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cullinan Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-10 | 2021-06-30 | -0.41 | -0.36 | 0.05 | 12 | ||
2023-03-09 | 2022-12-31 | -0.66 | -0.59 | 0.07 | 10 | ||
2021-05-14 | 2021-03-31 | 0.07 | -0.0017 | -0.0717 | 102 | ||
2024-11-06 | 2024-09-30 | -0.81 | -0.69 | 0.12 | 14 | ||
2024-05-15 | 2024-03-31 | -0.99 | -0.86 | 0.13 | 13 | ||
2023-08-10 | 2023-06-30 | -0.97 | -0.82 | 0.15 | 15 | ||
2022-03-17 | 2021-12-31 | -0.47 | -0.74 | -0.27 | 57 | ||
2022-05-16 | 2022-03-31 | -0.61 | -0.27 | 0.34 | 55 |
Cullinan Oncology Target Price Consensus
Cullinan target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cullinan Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Cullinan analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cullinan stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cullinan Oncology LLC, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCullinan Oncology Target Price Projection
Cullinan Oncology's current and average target prices are 8.54 and 33.00, respectively. The current price of Cullinan Oncology is the price at which Cullinan Oncology LLC is currently trading. On the other hand, Cullinan Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cullinan Oncology Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Cullinan Oncology Target Price
Cullinan Oncology Analyst Ratings
Cullinan Oncology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Cullinan Oncology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Cullinan Oncology's financials, market performance, and future outlook by experienced professionals. Cullinan Oncology's historical ratings below, therefore, can serve as a valuable tool for investors.Know Cullinan Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cullinan Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cullinan Oncology LLC backward and forwards among themselves. Cullinan Oncology's institutional investor refers to the entity that pools money to purchase Cullinan Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vr Adviser, Llc | 2024-12-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Kynam Capital Management, Lp | 2024-12-31 | 1.3 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Siren, L.l.c. | 1.2 M | Braidwell Lp | 2024-12-31 | 1.2 M | Nextech Invest Ag | 2024-12-31 | 1.1 M | Orbimed Advisors, Llc | 2024-09-30 | 1.1 M | Adage Capital Partners Gp Llc | 2024-12-31 | 1 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 7.6 M | Bvf Inc | 2024-12-31 | 5.8 M |
Cullinan Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 498.43 M.Market Cap |
|
Cullinan Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.30) | |
| Return On Capital Employed | (0.38) | (0.36) | |
| Return On Assets | (0.28) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
Determining Cullinan Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Cullinan Oncology is a good buy. For example, gross profit margin measures Cullinan Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cullinan Oncology's profitability and make more informed investment decisions.
Evaluate Cullinan Oncology's management efficiency
Cullinan Oncology LLC has return on total asset (ROA) of (0.204) % which means that it has lost $0.204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2653) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of February 2025, Return On Tangible Assets is likely to drop to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.36. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 26th of February 2025, Other Current Assets is likely to grow to about 15.8 M, while Non Current Assets Total are likely to drop about 4.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.84 | 10.33 | |
| Tangible Book Value Per Share | 9.84 | 10.33 | |
| Enterprise Value Over EBITDA | (1.55) | (1.63) | |
| Price Book Value Ratio | 0.84 | 0.88 | |
| Enterprise Value Multiple | (1.55) | (1.63) | |
| Price Fair Value | 0.84 | 0.88 | |
| Enterprise Value | -78.7 M | -74.8 M |
Cullinan Oncology LLC benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta (0.16) |
Basic technical analysis of Cullinan Stock
As of the 26th of February, Cullinan Oncology shows the Risk Adjusted Performance of (0.14), mean deviation of 2.48, and Standard Deviation of 3.12. Cullinan Oncology LLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cullinan Oncology LLC standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Cullinan Oncology LLC is priced correctly, providing market reflects its regular price of 8.54 per share. Given that Cullinan Oncology has information ratio of (0.21), we suggest you to validate Cullinan Oncology LLC's prevailing market performance to make sure the company can sustain itself at a future point.Cullinan Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cullinan Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cullinan Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cullinan Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cullinan Oncology's Outstanding Corporate Bonds
Cullinan Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cullinan Oncology LLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cullinan bonds can be classified according to their maturity, which is the date when Cullinan Oncology LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Cullinan Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cullinan Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (1.67) | |||
| Mean Deviation | 2.48 | |||
| Coefficient Of Variation | (492.05) | |||
| Standard Deviation | 3.12 | |||
| Variance | 9.73 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.66) | |||
| Treynor Ratio | (1.68) | |||
| Maximum Drawdown | 15.27 | |||
| Value At Risk | (6.27) | |||
| Potential Upside | 4.98 | |||
| Skewness | (0.07) | |||
| Kurtosis | 0.5623 |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (1.67) | |||
| Mean Deviation | 2.48 | |||
| Coefficient Of Variation | (492.05) | |||
| Standard Deviation | 3.12 | |||
| Variance | 9.73 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.66) | |||
| Treynor Ratio | (1.68) | |||
| Maximum Drawdown | 15.27 | |||
| Value At Risk | (6.27) | |||
| Potential Upside | 4.98 | |||
| Skewness | (0.07) | |||
| Kurtosis | 0.5623 |
Consider Cullinan Oncology's intraday indicators
Cullinan Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cullinan Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 8.54 | |||
| Day Typical Price | 8.54 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 34.5 |
Cullinan Oncology Corporate Filings
F4 | 21st of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Cullinan Stock media impact
Far too much social signal, news, headlines, and media speculation about Cullinan Oncology that are available to investors today. That information is available publicly through Cullinan media outlets and privately through word of mouth or via Cullinan internal channels. However, regardless of the origin, that massive amount of Cullinan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cullinan Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cullinan Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cullinan Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cullinan Oncology alpha.
Cullinan Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cullinan Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cullinan Oncology Corporate Management
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Mary Fenton | Chief Officer | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cullinan Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.